These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 26625262)

  • 1. Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survival.
    Maleux G; Deroose C; Laenen A; Verslype C; Heye S; Haustermans K; De Hertogh G; Sagaert X; Topal B; Aerts R; Prenen H; Vanbeckevoort D; Vandecaveye V; Van Cutsem E
    Acta Oncol; 2016; 55(4):486-95. PubMed ID: 26625262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
    Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
    AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
    [No Abstract]   [Full Text] [Related]  

  • 3. 90Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study.
    Hickey R; Lewandowski RJ; Prudhomme T; Ehrenwald E; Baigorri B; Critchfield J; Kallini J; Gabr A; Gorodetski B; Geschwind JF; Abbott A; Shridhar R; White SB; Rilling WS; Boyer B; Kauffman S; Kwan S; Padia SA; Gates VL; Mulcahy M; Kircher S; Nimeiri H; Benson AB; Salem R
    J Nucl Med; 2016 May; 57(5):665-71. PubMed ID: 26635340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That Affect Outcomes.
    Sofocleous CT; Violari EG; Sotirchos VS; Shady W; Gonen M; Pandit-Taskar N; Petre EN; Brody LA; Alago W; Do RK; D'Angelica MI; Osborne JR; Segal NH; Carrasquillo JA; Kemeny NE
    Clin Colorectal Cancer; 2015 Dec; 14(4):296-305. PubMed ID: 26277696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single-center experience of 302 patients.
    Saxena A; Meteling B; Kapoor J; Golani S; Morris DL; Bester L
    Ann Surg Oncol; 2015 Mar; 22(3):794-802. PubMed ID: 25323474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yttrium-90 Radioembolization as Salvage Therapy for Liver Metastases From Colorectal Cancer.
    Kalva SP; Rana RS; Liu R; Rachamreddy N; Dave B; Sharma A; Ganguli S; Rabito C; Kwak E; Blaszkowsky LS
    Am J Clin Oncol; 2017 Jun; 40(3):288-293. PubMed ID: 25374143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients.
    Klingenstein A; Haug AR; Zech CJ; Schaller UC
    Cardiovasc Intervent Radiol; 2013 Feb; 36(1):158-65. PubMed ID: 22526099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients.
    Bester L; Meteling B; Pocock N; Pavlakis N; Chua TC; Saxena A; Morris DL
    J Vasc Interv Radiol; 2012 Jan; 23(1):96-105. PubMed ID: 22079516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robust evidence for long-term survival with
    Jakobs TF; Paprottka KJ; Raeßler F; Strobl F; Lehner S; Ilhan H; Trumm CG; Fendler WP; Sommer W; Paprottka PM
    Eur Radiol; 2017 Jan; 27(1):113-119. PubMed ID: 27059858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases.
    Martin LK; Cucci A; Wei L; Rose J; Blazer M; Schmidt C; Khabiri H; Bloomston M; Bekaii-Saab T
    Clin Colorectal Cancer; 2012 Sep; 11(3):195-9. PubMed ID: 22277350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.
    Hendlisz A; Van den Eynde M; Peeters M; Maleux G; Lambert B; Vannoote J; De Keukeleire K; Verslype C; Defreyne L; Van Cutsem E; Delatte P; Delaunoit T; Personeni N; Paesmans M; Van Laethem JL; Flamen P
    J Clin Oncol; 2010 Aug; 28(23):3687-94. PubMed ID: 20567019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases.
    Lahti SJ; Xing M; Zhang D; Lee JJ; Magnetta MJ; Kim HS
    J Vasc Interv Radiol; 2015 Aug; 26(8):1102-11. PubMed ID: 26210240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization.
    Fan KY; Wild AT; Halappa VG; Kumar R; Ellsworth S; Ziegler M; Garg T; Rosati LM; Su Z; Hacker-Prietz A; Pawlik TM; Cosgrove DP; Hong KK; Kamel IR; Geschwind JF; Herman JM
    Contemp Clin Trials; 2016 Sep; 50():143-9. PubMed ID: 27520932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights into the Dose-Response Relationship of Radioembolization with Resin 90Y-Microspheres: A Prospective Cohort Study in Patients with Colorectal Cancer Liver Metastases.
    van den Hoven AF; Rosenbaum CE; Elias SG; de Jong HW; Koopman M; Verkooijen HM; Alavi A; van den Bosch MA; Lam MG
    J Nucl Med; 2016 Jul; 57(7):1014-9. PubMed ID: 26912436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system.
    Damm R; Seidensticker R; Ulrich G; Breier L; Steffen IG; Seidensticker M; Garlipp B; Mohnike K; Pech M; Amthauer H; Ricke J
    BMC Cancer; 2016 Jul; 16():509. PubMed ID: 27439702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of failure in colorectal patients with liver metastases after yttrium-90 radioembolization.
    Schonewolf CA; Patel B; Gensure RH; Narra V; Haffty BG; Nosher JL; Jabbour SK
    Am J Clin Oncol; 2014 Jun; 37(3):234-40. PubMed ID: 23275270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy.
    Sharma RA; Van Hazel GA; Morgan B; Berry DP; Blanshard K; Price D; Bower G; Shannon JA; Gibbs P; Steward WP
    J Clin Oncol; 2007 Mar; 25(9):1099-106. PubMed ID: 17369573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres.
    Mulcahy MF; Lewandowski RJ; Ibrahim SM; Sato KT; Ryu RK; Atassi B; Newman S; Talamonti M; Omary RA; Benson A; Salem R
    Cancer; 2009 May; 115(9):1849-58. PubMed ID: 19267416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization.
    Schmeel FC; Simon B; Luetkens JA; Träber F; Meyer C; Schmeel LC; Sabet A; Ezziddin S; Schild HH; Hadizadeh DR
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1531-1541. PubMed ID: 28317063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors.
    Jia Z; Paz-Fumagalli R; Frey G; Sella DM; McKinney JM; Wang W
    J Gastroenterol Hepatol; 2017 Sep; 32(9):1617-1623. PubMed ID: 28132407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.